Introduction The aim of this study was to assess the effectiveness of low-power thulium (30 W) and the duration necessary to eliminate adenomas at the level of the surgical capsule, as well as its impact on postoperative urinary and sexual function. Laser prostate enucleation (HoLEP) has been shown to be a safe procedure with a reduced risk of bleeding 3, shorter hospital stays 4, and a quicker features time 5 when compared to other BPH treatment options, i.e. open prostatectomy and transurethral resection of the prostate (TURP), which have some minimal and key adverse impacts such as dysuria, urinary frequency, sexual dysfunction, and sepsis 6. The premise behind adopting low-power laser enucleation is to give less energy to the surrounding structures but with similar outcomes to high-power ThuLEP and a lower incidence of postoperative dysuria, decreased storage LUTs, and improved erectile function. The history, digital rectal exam, international prostate symptom score (IPSS), urine analysis and culture, haemoglobin concentration (Hb), serum prostate-specific antigen (PSA) (preoperative and at 6 months), transrectal ultrasonography (TRUS), Urofiow, and post-void residual urine PVR were all performed on eligible individuals (after voiding residual urine).